Hot Pursuit     26-Sep-11
Orchid Chemicals slips as fire erupts at Chennai R&D unit
Orchid Chemicals & Pharmaceuticals fell 3.54% at Rs 175.55 at 13:37 IST on BSE after the company said that a fire broke out at a portion of the new drug discovery laboratory of its research subsidiary--Orchid Research Laboratories--in Chennai.

The announcement was made during trading hours today, 26 September 2011.

Meanwhile, the BSE Sensex was down 111.54 points, or 0.69%, to 16,050.52.

On BSE, 4.52 lakh shares were traded in the counter as against an average daily volume of 5.33 lakh shares in the past one quarter.

The stock hit a high of Rs 184.30 and a low of Rs 170.25 so far during the day. The stock had hit a 52-week low of Rs 165 on 9 August 2011. The stock had hit a 52-week high of Rs 344.40 on 26 October 2010.

The stock had underperformed the market over the past one month until 23 September 2011, falling 8.34% compared with the Sensex's 2.04% decline. The scrip had also underperformed the market in past one quarter, sliding 28.11% as against 8.83% decline in the Sensex.

The mid-cap pharmaceutical company has an equity capital of Rs 70.44 crore. Face value per share is Rs 10.

Orchid Chemicals & Pharmaceuticals said the fire erupted at a portion of the new drug discovery laboratory, located at the company's research subsidiary Orchid Research Laboratories at Sholinganallur in Chennai. The fire was brought under control by the Tamil Nadu Fire Services squad. The fire damaged office, laboratory equipment, furniture and building interiors. However, there were no human casualties, the company added.

Orchid Chemicals & Pharmaceuticals' net profit fell 28.1% to Rs 15.54 crore on 23.1% increase in net sales to Rs 373.76 crore in Q1 June 2011 over Q1 June 2010.

Orchid Chemicals & Pharmaceuticals is a vertically integrated company spanning the entire pharmaceutical value chain from discovery to delivery with established credentials in research, manufacturing and marketing. The firm enjoys a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system, cardio vascular segment, nutraceuticals and other oral and sterile products. Its pharmaceutical solutions include active pharmaceutical ingredients, finished dosage forms, new drug discovery, novel drug delivery systems and contract research and manufacturing services.

Previous News
  Orchid Pharma consolidated net profit rises 212.23% in the June 2024 quarter
 ( Results - Announcements 13-Aug-24   07:29 )
  Orchid Pharma to conduct AGM
 ( Corporate News - 18-Jul-24   20:35 )
  Orchid Pharma partners with Cipla to launch antibiotic drug - Cefepime-Enmetazobactam in India
 ( Corporate News - 28-Jun-24   19:23 )
  Orchid Pharma reports consolidated net loss of Rs 22.66 crore in the June 2020 quarter
 ( Results - Announcements 08-Sep-20   10:36 )
  Orchid Pharma announces board meeting date
 ( Corporate News - 10-Aug-24   12:49 )
  Orchid Pharma AGM scheduled
 ( Corporate News - 10-Jul-23   10:06 )
  Orchid Pharma hits 52-week high on receiving EMA nod for Exblifep
 ( Hot Pursuit - 30-Jan-24   12:55 )
  Orchid Pharma to announce Quarterly Result
 ( Corporate News - 30-Oct-23   19:26 )
  Orchid Pharma reports standalone net loss of Rs 54.31 crore in the March 2020 quarter
 ( Results - Announcements 30-Jun-20   12:44 )
  Orchid Pharma to convene board meeting
 ( Corporate News - 07-Feb-22   10:23 )
  Orchid Pharma partners with Cipla for pan-India distribution of Cefepime-Enmetazobactam
 ( Hot Pursuit - 29-Jun-24   10:08 )
Other Stories
  Avantel Q2 PAT jumps 42% YoY to Rs 23 cr
  05-Oct-24   17:03
  Equitas SFB total deposits jump 29% YoY in Q2 FY25
  05-Oct-24   16:28
  Ujjivan SFB total deposits rises 17% in Q2 FY25
  05-Oct-24   15:34
  L&T Finance retail disbursements jump 12% YoY in Q2 FY25
  05-Oct-24   14:31
  Bandhan Bank records over 21% YoY jump in loan book during Q2 FY25; deposits at Rs 1.42 lakh crore
  05-Oct-24   13:32
  Lupin's Pune-based biotech facility gets 5 observations from US FDA
  05-Oct-24   13:20
  Macrotech Developers pre-sales jumps 21% YoY in Q2 FY25
  05-Oct-24   09:04
  UCO Bank’s total advances jump 19% YoY in Q2 FY25
  04-Oct-24   15:15
  Vakrangee Ltd leads losers in 'A' group
  04-Oct-24   15:00
  Kamdhenu Ventures Ltd leads losers in 'B' group
  04-Oct-24   14:45
Back Top